In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss: How ...

Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Marvell Technology (NASDAQ: MRVL), VF Corp. (NYSE: VFC), and Hims & Hers Health (NYSE: HIMS) are three of those names, ...